Skip to content
Peptideworth

Peptide guide

GHK-Cu: What the Evidence Actually Shows

Also calledcopper tripeptidecopper tripeptide-1copper peptideglycyl-L-histidyl-L-lysine-CuGHK

GHK-Cu is a copper-carrying tripeptide with a genuinely interesting biology and a very short human record. Its entire randomized literature is three papers: one in rabbits, and two in people. Both human trials applied it to skin, and both found no significant difference from their comparators on the things they measured with instruments — redness, wrinkles, skin quality, ulcer size. Nothing has ever been injected into a person in a controlled trial. That matters more here than usual, because the FDA has split its own position by route: the non-injectable form sits on its list of substances still under evaluation for compounding, while the injectable form is the one the agency has published a safety concern about, citing immunogenicity risk and limited human data.

By Grant Delaney, Research Editor
Randomized human trials

2both topical

Humans randomized, ever

99across 1992 and 2006

Injected human trials

0any condition, any phase

FDA compounding status

Route-splitinjectable route excluded

Compound

What it is

GHK-Cu is three amino acids — glycine, histidine and lysine — bound to a copper ion. The tripeptide occurs naturally in human plasma and binds copper with high affinity, which is where its biological interest begins: copper is a cofactor for enzymes involved in building and remodeling connective tissue, and GHK is a way of delivering it to a specific place. It was first described as a growth factor for cultured cells, and the work that made its reputation showed that injecting it into implanted wound chambers in rats increased collagen, glycosaminoglycans and total protein in a dose-dependent way, while a control tripeptide did nothing. Commercially it lives two lives. As copper tripeptide-1 it is a long-established cosmetic ingredient in serums and creams. As GHK-Cu it is dispensed as a compounded injectable, which is a different product in a different regulatory category with a different evidence base — or, more precisely, without one.3

Mechanism

How it works

The proposed chain is coherent and much of it has been demonstrated, in animals. GHK-Cu delivers copper to tissue, stimulates the synthesis of collagen and other matrix components, modulates the enzymes that break matrix down, and is reported to fall in human plasma with age — which is the observation the anti-aging framing is built on. In rat wound chambers, sequential injections produced a concentration-dependent rise in collagen, with collagen synthesis stimulated about twice as much as non-collagen protein, and increases in type I and type III collagen messenger RNA. Applied topically to open wounds in rabbits, it shrank the wound faster than zinc oxide or no treatment. What none of that establishes is what happens when the same molecule is injected into a person. A mechanism demonstrated in a rat's implanted wound chamber is evidence that the molecule does something to connective tissue. It is not evidence about a human joint, tendon, scalp or face, and it says nothing at all about the dose or schedule anyone should use.3,5

Evidence

What the trials found

Early human

Evidence strength: Early human. Small, open-label, or phase 1/2 trials. Promising, unproven.

The whole randomized record is three papers, and reading them is quick. One is a 2006 veterinary study in 18 rabbits, comparing topical tripeptide-copper against zinc oxide and no treatment on surgical wounds; the copper complex closed wounds faster than both. The two human trials are the ones that matter, and both were negative on their objective measures. In a 2006 trial, patients who had undergone carbon dioxide laser resurfacing around the mouth were randomized to an after-care regimen with or without topical GHK-Cu; 13 completed it. Computer analysis and blinded evaluators found no statistically significant difference between the groups in how quickly redness resolved, and no difference in wrinkles or overall skin quality. All patients improved; the groups did not differ. The one measure that did differ was the patients' own questionnaire, where those using GHK-Cu reported greater improvement in overall skin quality. In a 1992 trial, 86 patients with venous stasis ulcers were randomized to 1% silver sulfadiazine cream, a 0.4% tripeptide-copper cream, or an inert vehicle placebo. Silver sulfadiazine significantly reduced ulcer size compared with both of the others, and there was no difference between the copper cream and the placebo. Two randomized human trials, 99 patients between them, three decades apart, both applied to skin, and neither showed an objective effect of the copper complex.1,2,5

13

Patients in the skin trial

No significant difference in redness, wrinkles or skin quality by computer analysis or blinded evaluation. Only the self-report questionnaire favored it.

3

Registered studies, all topical or device

A control search for collagen in the same registry returns 1,834, so the number is about the compound rather than the query.

—

Effect of an injection in humans

No controlled trial has ever injected it into a person. The injected evidence is rat wound chambers.

Where the GHK-Cu evidence sits, by route and species

Topical, humans
2 randomized studies
Topical, animals
1 randomized studies
Injected, humans
0 randomized studies
How to read the evidence meter

How to read the evidence meter

Four steps, weakest to strongest. Most peptides sold for a goal light up one. We show the step the published human evidence actually reaches — not the step the seller implies.

  1. AnecdotalUser reports and forum consensus. No controlled data.
  2. Animal onlyRodent or cell studies. Nothing published in humans.
  3. Early humanSmall, open-label, or phase 1/2 trials. Promising, unproven.
  4. Randomized trialsRandomized controlled trials in humans, at scale.

Timeline

Development pipeline

  1. Complete

    Preclinical

    Rat wound chambers and rabbit wounds — where the collagen findings come from

  2. 2 — Current step

    Topical human trials

    Two completed, 99 patients, both null on objective endpoints; a phase 2 gel trial is recruiting

  3. 3 — Not reached

    Injected human trials

    None registered, none published

  4. 4 — Not reached

    FDA review & approval

    The injectable route is not on the category 1 list

Summary

What the evidence does — and doesn't — support

What has not been studied

Nobody has injected GHK-Cu into a person in a controlled trial. There is no human dose, no human schedule, no human safety data by that route, and the FDA's own note on it cites immunogenicity risk alongside limited human data. The two human trials that exist put it on the skin.
What the evidence supports
  • In rats, injections into implanted wound chambers raised collagen and matrix accumulation in a concentration-dependent way, while a control tripeptide did not.
  • Applied topically to open wounds in rabbits, it closed them faster than zinc oxide or no treatment.
  • It is a real human plasma peptide that binds copper with high affinity, and copper is genuinely a cofactor for connective-tissue enzymes.
What it does not support
  • Anything by injection in a human — no controlled trial has ever been run, in any condition.
  • Faster healing or better skin after laser resurfacing: the trial that tested it found no objective difference across 13 patients.
  • Wound closure better than an inert cream: the 86-patient ulcer trial found no difference from placebo.
Show 1 more
  • Joint, tendon or recovery claims. A 2026 orthopedic review found no clinical data supporting musculoskeletal use.

Reality check

The catch

Everything that has ever been tested in a person was rubbed on, and neither test worked on the measures that did not rely on the patient's opinion. The 2006 laser-resurfacing trial found no difference in redness, wrinkles or skin quality by computer analysis or blinded evaluation across 13 patients; only the self-report questionnaire favored GHK-Cu. The 1992 ulcer trial found the copper cream no better than an inert placebo across 86 patients. Meanwhile the compound is dispensed as an injection, and there is no controlled trial of injected GHK-Cu in a human being for anything — the registry lists three GHK-Cu studies and all three are topical or applied by a device. The FDA has made that same distinction structural. Its list of bulk substances still under evaluation for compounding names "GHK-Cu (except for injectable routes of administration)", and the injectable route instead appears on the agency's published safety-concern list with this note: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." The one route with human evidence is the one FDA left on the list. The route with none is the one it did not.

Dosing

Dosing evidence

There is no human dose for injected GHK-Cu, established or otherwise. The 2006 human trial used a commercial topical skin-care regimen applied after laser resurfacing and assessed at 12 weeks; the 1992 trial used a 0.4% cream on ulcers. Those are concentrations for a preparation you spread, and they do not convert into milligrams in a syringe. The animal work used sequential injections into implanted chambers at a range of concentrations chosen to draw a dose-response curve in rats, which is a laboratory design rather than a treatment schedule. A 2026 review of injectable peptide therapy written for orthopedic and sports-medicine physicians makes the point in the plainest terms available, concluding of this whole class that information regarding the indications, dosing, frequency and duration of treatment remains unknown. This page reports what studies used. It does not tell any reader what to take, and there is no published figure it could honestly offer if it wanted to.1,4

Already have a dose in mind? Our reconstitution calculator converts it to syringe units. It does not suggest one.

Safety

Safety and side effects

There is no human safety data for injected GHK-Cu, because there has been no controlled human trial of injected GHK-Cu. That is the entire answer, and it is worth stating rather than padding. Topically, copper peptides have been in cosmetic use for decades without a recognized safety signal, and the two human trials reported no notable adverse events — but a compound applied to intact skin and a compound delivered under it are different exposures. The FDA's stated concern about the injectable route is not about copper toxicity; it is about the peptide itself, specifically the risk of an immune response driven by aggregation and by peptide-related impurities, in a setting where there are limited data in humans to judge by. A 2026 review of injectable peptides in orthopedic practice reaches the same place from the clinical side, noting that GHK-Cu shows promise in wound healing and anti-inflammatory work but that no clinical data support its use for musculoskeletal conditions. What that means practically is that the safety of a compounded GHK-Cu injection is the safety of the pharmacy that made it, and nobody has published a study that would tell you otherwise.4

Under active FDA restriction — compliant pharmacies decline to sell it.

Three trials, and one of them is rabbits

The complete randomized literature on GHK-Cu, across every name the molecule goes by, is three papers.

The first, from 2006, is veterinary: 18 rabbits with surgical wounds, randomized to topical tripeptide-copper, zinc oxide, or nothing. The copper complex closed wounds faster than both comparators, and granulation tissue arrived sooner 5. It is a clean little study and it is about rabbits.

The other two are in people, and both are worth reading in full because both are usually cited as if they were positive.

2006, carbon dioxide laser resurfacing. Patients had skin around the mouth resurfaced with a laser, then were randomized to an after-care regimen with or without GHK-Cu products. Thirteen completed. Redness was measured by computer software and by blinded evaluators; wrinkles and overall skin quality were assessed at 12 weeks. The result: no statistically significant difference between the groups on any of it. Every patient improved — that is what happens after laser resurfacing — and the groups did not differ from each other. The single measure that did differ was the patients' own questionnaire, on which the GHK-Cu group reported greater improvement in overall skin quality (P = .04) 1.

1992, venous stasis ulcers. Eighty-six evaluable patients, randomized between 1% silver sulfadiazine cream, a 0.4% tripeptide-copper cream, and an inert vehicle placebo. Silver sulfadiazine significantly reduced ulcer size compared with both of the others. Between the copper cream and the placebo, there was no difference 2.

Ninety-nine human patients, thirty years apart, both topical, both null where the measurement did not depend on the patient's impression. That is not a reason to conclude GHK-Cu does nothing; two small trials cannot establish that either. It is a reason to be careful with the phrase "clinically studied", which is technically true and, on this record, does not mean what a buyer will assume it means. Our note on what sample size buys you covers why 13 patients cannot settle a question in either direction.

Full analysis — 4 more sectionsNothing has been injected into a person · The FDA drew its line at the route · What a sports-medicine review found · What would change the picture

Nothing has been injected into a person

There is no controlled trial of injected GHK-Cu in a human, for any purpose.

The registry says the same. ClinicalTrials.gov lists three studies under GHK-Cu: a completed device study of facial skin quality, a phase 2 trial of a topical gel on standardized punch-biopsy wounds, and a not-yet-recruiting study of a patch, measuring circulating GHK levels in healthy adults. Topical, topical, patch. A control search for collagen in the same index returns 1,834 studies, so the number three is a fact about GHK-Cu rather than about the query.

One search lesson, since it recurs: "copper tripeptide" returns zero registered studies for the same molecule that "GHK-Cu" returns three for. The registry indexes it under one name and not the other. A null result from the wrong string is not an absence of research — and this cuts both ways, which is why this page reports what reading the records shows rather than what counting them suggests.

What does exist by an injected route is animal work, and it is genuinely the foundation of the compound's reputation. The 1993 study in the Journal of Clinical Investigation implanted wire-mesh chambers under the skin of rats and injected GHK-Cu into them; collagen, glycosaminoglycans, DNA and total protein all rose in a concentration-dependent way, collagen synthesis roughly twice as much as non-collagen protein, while a control tripeptide did nothing 3. That is a real and well-controlled finding about connective tissue in a rat chamber. It is the distance between that and a human shoulder that this page exists to measure.

The FDA drew its line at the route

This is the part most worth knowing, because it is unusually specific.

The FDA maintains a list of bulk substances nominated for use in pharmacy compounding, sorted into categories. Category 1 is "under evaluation" — substances the agency has not identified significant safety risks with, pending review. The current list, updated May 2026, contains this entry:

> GHK-Cu (except for injectable routes of administration)

The parenthesis is the whole story. The nominations for GHK-Cu were withdrawn in April 2026; in May a nominator clarified that it had meant to withdraw only the injectable route and wished to keep the non-injectable nomination, so the non-injectable form went back onto the category 1 list and the injectable form did not.

Separately, the agency publishes a page summarizing identified safety risks for compounding substances. It carries a row for "GHK-Cu (for injectable routes of administration)" reading:

> Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.

The FDA has also announced it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu should go on the 503A bulks list at all.

So the regulatory position and the evidence position point the same way, which does not happen often. The route with human trials behind it — on the skin — is the one that remains under evaluation. The route with no human trials behind it is the one carrying a published concern and no nomination. Our compounding explainer sets out what those lists govern; for the two peptides in this category that sit further down the same lists, see BPC-157 and TB-500.

What a sports-medicine review found

A 2026 narrative review in the American Journal of Sports Medicine, written to help orthopedic physicians answer patients asking about injectable peptides, assessed GHK-Cu alongside BPC-157, TB-500, tesamorelin and others 4. Its verdict on GHK-Cu was that it shows promise in wound healing and anti-inflammatory effects, and that no clinical data support its use for musculoskeletal conditions. Its verdict on the class was broader and blunter: information regarding indications, dosing, frequency and duration of treatment remains unknown.

That is a fair summary of where a reader stands. The biology is not fringe. The human evidence is two small topical trials that did not separate from their comparators, and no injected trial at all.

What would change the picture

A randomized trial of injected GHK-Cu in humans, with an objective endpoint and a placebo arm. Given the FDA's stated concern about immunogenicity, a trial would also need to measure whether people develop antibodies to it — which nobody currently knows, because nobody has looked in a controlled setting.

The topical question is easier and nearly as open: the phase 2 gel trial now recruiting, on standardized punch-biopsy wounds, will produce a cleaner answer about skin than either of the two existing human trials managed. Until those read out, "clinically studied" means 99 patients, three decades apart, both times applied to the surface.

Questions

Frequently asked questions

Are there human trials of GHK-Cu?

Two, both topical. A 2006 trial applied it after carbon dioxide laser resurfacing in 13 patients and found no significant difference from the control regimen in redness, wrinkles or skin quality by computer analysis or blinded evaluation — only the patients' own questionnaire favored it. A 1992 trial tested a 0.4% cream on venous stasis ulcers in 86 patients and found it no better than an inert placebo.

Is there any evidence for injected GHK-Cu?

None in humans. There is no controlled trial of injected GHK-Cu in a person, and the three studies registered on ClinicalTrials.gov are all topical or applied by a device. The injected evidence is animal work, principally a 1993 study that injected it into implanted wound chambers in rats and measured collagen accumulation.

What does the FDA say about GHK-Cu?

It has split its position by route. The list of bulk substances still under evaluation for compounding names "GHK-Cu (except for injectable routes of administration)". For the injectable route, the agency's published safety summary says compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to aggregation and peptide-related impurities, and that there are limited data in humans. It intends to consult its compounding advisory committee before the end of February 2027.

Is GHK-Cu the same as copper peptides in skincare?

Same molecule, different product. As copper tripeptide-1 it has been a cosmetic ingredient for decades, and topical use is where all the human research sits. A compounded injectable is a different preparation in a different regulatory category, and no trial has tested it in a person.

Why do searches for copper peptide research come up empty?

Because the search term decides the answer. ClinicalTrials.gov returns three studies for "GHK-Cu" and zero for "copper tripeptide", which is the same molecule under the name the registry does not index it by. A null result from one phrasing is not an absence of research, and it is worth checking both before concluding anything.

Does GHK-Cu help joints, tendons or recovery?

No clinical data support that. A 2026 review in the American Journal of Sports Medicine, written for orthopedic physicians fielding these questions, concluded that GHK-Cu shows promise in wound healing and anti-inflammatory work but that no clinical data support its use for musculoskeletal conditions, and that dosing, frequency and duration remain unknown across this class.

Glossary

Key terms

Show definitions
GHK-Cu
Glycine, histidine and lysine bound to a copper ion. It occurs naturally in human plasma and has been a cosmetic ingredient, as copper tripeptide-1, for decades.
Immunogenicity
The risk that the body mounts an immune response against an injected peptide. It is the specific concern the FDA names for injectable GHK-Cu, driven by aggregation and impurities.
Category 1 (compounding)
The FDA's list of nominated bulk substances still under evaluation, with no significant safety risk identified so far. GHK-Cu is on it only for non-injectable routes.

Sources

References

Show all 5 sources
  1. Miller TR, Wagner JD, Baack BR, et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. https://pubmed.ncbi.nlm.nih.gov/16847171/
  2. Bishop JB, Phillips LG, Mustoe TA, et al. (1992). A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery. https://pubmed.ncbi.nlm.nih.gov/1495150/
  3. Maquart FX, Bellon G, Chaqour B, et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. The Journal of Clinical Investigation. https://pubmed.ncbi.nlm.nih.gov/8227353/
  4. Mayfield CK, Bolia IK, Feingold CL, et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41476424/
  5. Cangul IT, Gul NY, Topal A, et al. (2006). Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Veterinary Dermatology. https://pubmed.ncbi.nlm.nih.gov/17083573/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.